Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192682 | 1.00 | RIPK1 (0.62) | RIPK1HPGDSMN1; SMN2LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL30279534 | 0.98 | RIPK1 (0.60) | RIPK1HPGDSMN1; SMN2LMNAKMT2A | |
| Fumaric Acid SCHEMBL30279572 | 0.91 | RIPK1 (0.54) | RIPK1HPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL10150926 | 0.83 | HTT (0.50) | HPGDKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL14241867 | 0.83 | TAAR1 (0.56) | RAB9A | |
| SCHEMBL23134945 | 0.82 | HPGD (0.57) | RIPK1HPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL4038051 | 0.82 | HPGD (0.57) | RIPK1HPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL29941696 | 0.81 | RIPK1 (0.61) | RIPK1HPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1685923 | 0.81 | RIPK1 (0.61) | RIPK1HPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL23135761 | 0.81 | KMT2A (0.62) | RIPK1HPGDSMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715631-A | 6 inhibitor of TRAF | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 2019-05-03 | — | — | CN | claimed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| CN-106259371-A | A kind of Herbicidal composition for rice field | 浙江天丰生物科学有限公司 | 2017-01-04 | — | — | CN | disclosed |
| CN-106234401-A | A kind of Herbicidal composition for rice field | 浙江天丰生物科学有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-106106466-A | A kind of containing metamifop and different grass pine herbicidal composition | 浙江天丰生物科学有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-106070251-A | A kind of for agent for removing grass in paddy field synergistic composition | 广东中迅农科股份有限公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2016012333-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| EP-1586552-B1 | PROCESS FOR PRODUCING BENZYLAMINE DERIVATIVE | IHARA CHEMICAL IND CO (JP) | 2010-08-25 | — | — | EP | disclosed |
| CN-100503551-C | Process for producing benzylamine derivative | IHARA CHEMICAL IND CO (JP) | 2009-06-24 | — | — | CN | disclosed |
| US-7326813-B2 | Process for producing benzylamine derivative | IHARA CHEMICAL INDUSTRY (JP) | 2008-02-05 | — | — | US | disclosed |
| US-20060155141-A1 | Process for producing benzylamine derivative | ITO AKINORI | 2006-07-13 | — | — | US | disclosed |
| CN-1802343-A | Process for producing benzylamine derivative | IHARA CHEMICAL IND CO (JP) | 2006-07-12 | — | — | CN | disclosed |
| EP-1586552-A1 | PROCESS FOR PRODUCING BENZYLAMINE DERIVATIVE | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155141-A1 | Process for producing benzylamine derivative | BRD7, BRD1, BRD2 | RIPK1 4019/4885HPGD 2426/4885SMN1; SMN2 4813/4885 |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | RIPK1 670/4885HPGD 2492/4885SMN1; SMN2 2921/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | RIPK1 882/4885HPGD 4394/4885SMN1; SMN2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.